Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Completed · Phase 2 · Has a placebo group

Conditions studied: Cystic Fibrosis

In brief

This study is a multiple within participant crossover study to evaluate the effect of ivacaftor on lung function in participants aged 12 years and older with cystic fibrosis (CF) who have phenotypic or molecular evidence of residual CF transmembrane conductance regulator (CFTR) function.

Key facts

Study ID
NCT01685801
Run by
Vertex Pharmaceuticals Incorporated
People needed
24
Starts
2012-09-01
Expected to finish
2014-04-01
Last updated by the study team
2015-05-19

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.